The capstone: the commercial market pays the most, has moved the least, and now has the tools it always lacked.
Across this curriculum, Medicare has been the setting where payment reform was tested at scale, Medicaid where it was adapted to a harder population, and Medicare Advantage where capitation reached the majority of a program. The commercial market is where the most money is spent per unit of care and where the least has changed.
The scorecard
| Dimension | Where the commercial market stands |
|---|---|
| Prices paid | Highest of any payer, averaging 254 percent of Medicare for hospital services |
| Price variation | Extreme, from below 200 percent to above 300 percent of Medicare by state |
| Adoption of population-based payment | Trails Medicare, concentrated in a few markets |
| Quality measurement | Weakest public information despite the largest covered population |
| Purchaser capability | Limited outside the largest self-funded employers |
| Legal tools available | Substantially strengthened since 2021 |
What is genuinely true on both sides
In the market’s favor: it is the least constrained payer. A self-funded employer can design almost any arrangement it can negotiate, without a rulemaking process or a statutory authority. The best-evidenced commercial result, the Alternative Quality Contract, outperformed most federal models, which shows the freedom is usable when a capable provider organization is on the other side.
Against it: that freedom has mostly not been used. The dominant strategies remain cost shifting to employees through deductibles and network restrictions, both of which reduce employer spending without changing how care is produced. And the prices underneath everything are the highest in the system, sustained by consolidation that continues to increase.
What has actually changed
Three things are new enough that their consequences are not yet visible in outcomes:
- Prices are public. Negotiated rates exist in machine-readable files for the whole market.
- Gag clauses are prohibited. An employer bearing claims risk can no longer be barred from seeing its own data.
- Fiduciary duty is enforceable in a way it was not. Compensation must be disclosed, and litigation testing the theory is underway.
For decades the honest defense of employer passivity was that employers could not see what they were buying. That defense is gone. Whether employers now act is an open empirical question, and the answer is not yet in the data.
Worth remembering: the tempting conclusion is that transparency plus fiduciary duty will produce a more efficient commercial market. The evaluation course counsels against assuming it. Information changes behavior only when someone has the capability and the incentive to act, and Module 5 catalogued four structural obstacles that none of these changes touch: fragmented purchasing, provider consolidation, employee turnover, and limited internal capability. The barriers that were removed were real. The ones that remain are the harder ones. A forecast that the commercial market is about to transform should be held loosely, and revisited against evidence rather than against expectation.
The through-line
This course sits at the end of the curriculum because it requires everything before it. Reading a commercial contract needs the contracting course. Judging a savings claim needs the evaluation course. Benchmarking prices needs the Medicare course. Understanding what a provider organization must build to accept risk needs the ACO and primary care courses. The commercial market is where all of it is applied with the fewest rules and the least guidance, which makes judgment matter more here than anywhere else.
Key takeaways
- Commercial payers pay the most per service and have adopted population-based payment least.
- The market’s freedom to design arrangements is real and has largely gone unused.
- Transparency, the gag clause ban, and fiduciary disclosure removed the barriers to informed purchasing.
- Fragmentation, consolidation, turnover, and limited capability remain, and none were addressed by those changes.
Sources
- Prices Paid to Hospitals by Private Health Plans: Findings from Round 5.1 of an Employer-Led Transparency Initiative (RAND) (opens in a new tab)
- Song et al., Health Care Spending, Utilization, and Quality 8 Years into Global Payment, NEJM 2019 (opens in a new tab)
- CMS, Gag Clause Prohibition Compliance Attestation (opens in a new tab)
Check your understanding
What is the most defensible summary of value-based care in the commercial market?
Commercial prices average 254 percent of Medicare, adoption of population-based arrangements trails Medicare, and the transparency and fiduciary changes are recent enough that their effect on purchaser behavior is not yet established.